76 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
ADUS Addus HomeCare Corporation $68.95 $806.53M N/A
Article Searches
Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates http://www.zacks.com/stock/news/259598/conatus-cnat-q1-loss-narrows-y-y-revenues-beat-estimates?cid=CS-ZC-FT-259598 May 05, 2017 - Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y http://www.zacks.com/stock/news/254558/orexigen-posts-wider-than-expected-loss-in-q4-sales-up-y-y?cid=CS-ZC-FT-254558 Mar 29, 2017 - Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.
Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion http://www.zacks.com/stock/news/254428/novo-nordisk-positive-chmp-nod-for-tresiba-label-expansion?cid=CS-ZC-FT-254428 Mar 28, 2017 - Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.
VIVUS to Regain Commercial Rights for Stendra from Sanofi http://www.zacks.com/stock/news/254404/vivus-to-regain-commercial-rights-for-stendra-from-sanofi?cid=CS-ZC-FT-254404 Mar 28, 2017 - VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.
Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA http://www.zacks.com/stock/news/254097/roches-rituxan-gets-breakthrough-therapy-designation-by-fda?cid=CS-ZC-FT-254097 Mar 24, 2017 - Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.
Allergan's Restasis Now Available in Multidose Bottle in U.S. http://www.zacks.com/stock/news/253868/allergans-restasis-now-available-in-multidose-bottle-in-us?cid=CS-ZC-FT-253868 Mar 23, 2017 - Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.
Alexion (ALXN) Files for Soliris' Label Expansion in Japan http://www.zacks.com/stock/news/253867/alexion-alxn-files-for-soliris-label-expansion-in-japan?cid=CS-ZC-FT-253867 Mar 23, 2017 - Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).
Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study http://www.zacks.com/stock/news/253841/ultragenyxs-seizure-candidate-ux007-fails-in-phase-ii-study?cid=CS-ZC-FT-253841 Mar 23, 2017 - Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.
Keryx's Auryxia Added to Largest Medicare Part D Plan http://www.zacks.com/stock/news/253757/keryxs-auryxia-added-to-largest-medicare-part-d-plan?cid=CS-ZC-FT-253757 Mar 22, 2017 - Keryx Biopharmaceuticals, Inc. (KERX) announced that the nation's largest Medicare Part D plan sponsor has added Auryxia (ferric citrate) to its Medicare Part D plan formularies.
Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down http://www.zacks.com/stock/news/253718/array-biopharmas-nda-for-cancer-drug-withdrawn-shares-down?cid=CS-ZC-FT-253718 Mar 22, 2017 - Shares of Array BioPharma Inc. (ARRY) slipped 2.30% after the company announced that it has withdrawn its new drug application (NDA) for its pipeline candidate, binimetinib, from the FDA's Division of Oncology Products 2.

Pages: 12345678

<<<Page 6>